

GARDP: Working Globally to Address the Antimicrobial Crisis

Dr Lauren Jankelowitz

Access Lead: DNDi GARDP Southern Africa




Antibiotics are the foundation of modern medicine



These drugs have helped extend life expectancy by 23 years,
protecting us against harmful bacteria.

Can you imagine a world without them?



Superbugs are emerging everywhere and outsmart even the best of available antibiotics.

Currently we are losing this race. We need more innovation to keep up.

Even the most common infections are becoming more difficult to treat



Pneumonia



**Abdominal
infections**



**Urinary tract
infections**

AMR BURDEN IN AFRICA

- **Sub-Saharan Africa bears the greatest burden of deaths** from antibiotic resistance.
- In 2019, more than half of those who died were **children under the age of 5**.
- Without new antibiotics, by 2050, **over 4 million people in African countries could die** of drug-resistant infections each year





Our
Vision

Our
Mission



All infections are treatable
for everyone, everywhere

We work with partners
to **accelerate the**
development and access to
treatments for
drug-resistant infections

Addressing the most urgent threats to public health



Sepsis in children and newborns

1 in 5 deaths due to antibiotic resistance occur in children.
214,000 newborns die each year.



Serious bacterial infections in adults

Patients undergoing common medical procedures, such as C-section, hip replacement, or chemotherapy, are at risk of acquiring bacterial infections that cannot be easily treated with commonly used antibiotics.



Sexually transmitted infections

Sexually transmitted infections caused by bacteria may become untreatable with the rise of superbugs, especially gonorrhoea.



CHILDREN'S ANTIBIOTICS



Identified 3 potential combination treatments for neonatal sepsis

Completed one of the largest studies on babies with sepsis—3,200 newborns in 11 countries—and identified 3 promising antibiotics for use in combination (amikacin, fosfomycin, and flomoxef)



Public health clinical trial launched

that will validate the 3 new combinations alongside currently used antibiotic combinations



Paediatric studies on new antibiotics

Supporting paediatric studies for cefiderocol and cefepime- taniborbactam



SERIOUS BACTERIAL INFECTIONS



A promising new antibiotic on track for regulatory submission

Welcomed positive results in a phase 3 trial of cefepime- taniborbactam by Venatorx Pharmaceuticals. If approved, this will be the first antibiotic treatment to be launched in collaboration with GARDP



An approved antibiotic treatment

Signed license and collaboration agreements with Shionogi and CHAI to expand access to the antibiotic cefiderocol in 135 countries – mostly low- and middle-income countries

SEXUALLY TRANSMITTED INFECTIONS



A new treatment for gonorrhoea in late-stage development

Conducting a global phase 3 trial in 16 sites across 5 countries to evaluate zoliflodacin, an innovative oral treatment for gonorrhoea

Completed the manufacturing of the final drug product for registration and commercialization



GARDP sites in Africa

Sexually transmitted infections: A new treatment for gonorrhoea

- South Africa - 6 sites in clinics and communities

Serious bacterial infections: Observational study

- South Africa - 5 hospitals across 4 provinces

Neonatal sepsis: Observational study

- Tygerberg Hospital, Chris Hani Baragwanath Academic Hospital, Charlotte Maxeke Johannesburg Academic Hospital in South Africa
- Kilifi County Hospital in Kenya
- Mulago Hospital in Uganda


Neonatal sepsis: Clinical trial

- South Africa: Chris Hani Baragwanath Hospital, Charlotte Maxeke Johannesburg Academic Hospital, Tygerberg Hospital



DNDI GARDP SOUTHERN AFRICA: A KEY PART OF GARDP'S GLOBAL NETWORK


- Co-founded by GARDP and the Drugs for Neglected Diseases initiative (DNDi)
- Began operations in 2019 as a non-profit company in South Africa
- Carried out two clinical trials on paediatric HIV and advanced HIV for DNDi in South Africa
- Conducts clinical trials and studies in GARDP's neonatal sepsis, serious bacterial infections and STI programmes at sites across South Africa.
- Works with a broad range of partners on developing treatments and access to medicines for both GARDP and DNDi
- By late-2023, we had grown to a team of 13 employees and several expert consultants



Opportunities for GARDP in Africa

- **Encourage and promote** clinical trial networks for sepsis and sexually transmitted infections
- **Support pharmaceutical manufacturing strategies** to boost Africa's supply chain resilience
- **Engage local regulators** on AMR challenges and solutions
- **Work with partners** to speed up registration of antibiotics, access to medicines and stewardship





Financial contribution from
Public Health Agency of Canada / Agence de la santé publique du Canada



Ministry of Health, Welfare and Sport



Co-funded by the European Union



Federal Ministry of Education and Research



Gouvernement Princier / PRINCIPAUTÉ DE MONACO



GAMRIF

Leo Model Foundation



wellcome



Schweizerische Eidgenossenschaft / Confédération suisse / Confederazione Svizzera / Confederaziun svizra

Swiss Confederation



Ministry of Foreign Affairs

Thank you

